Favezelimab

Modify Date: 2024-04-06 08:26:47

Favezelimab structure	Common Name	Favezelimab
	CAS Number	2231068-83-8	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Favezelimab

Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902)[1][2].

Name	Favezelimab

Description	Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902)[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
References	[1]. Carmen Belli, et al. Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies. Cancers (Basel). 2022 Sep 1;14(17):4278. [2]. Gareth P. Gregory, et al. Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: A Phase I/II study. Cancer Res (2019) 79 (13_Supplement): CT106.

Description

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

References

[1]. Carmen Belli, et al. Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies. Cancers (Basel). 2022 Sep 1;14(17):4278.

[2]. Gareth P. Gregory, et al. Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: A Phase I/II study. Cancer Res (2019) 79 (13_Supplement): CT106.

No Any Chemical & Physical Properties

Favezelimab

Use of Favezelimab

Names

Favezelimab Biological Activity

Chemical & Physical Properties